Navigation Links
Preventing tuberculosis reactivation
Date:10/18/2007

Tuberculosis (TB) is the leading cause of death due to infectious disease in the world today. It is estimated that 2 billion people are currently infected, and although most people have latent infection, reactivation can occur. This paper by Denise Kirschner and colleagues, publishing in PLoS Computational Biology, conducts virtual clinical trials to examine the causes of reactivation.

Tumor necrosis factor alpha (TNF) is a protein that facilitates cellcell communication during an inflammatory immune response. Animal models have shown that TNF is vital for control of TB infection. However, anti-TNF treatments are common therapies for treating autoimmune diseases, and this can cause an unwanted side effect of reactivating latent TB. Kirschner has developed a computational model that can quickly perform virtual clinical trials to predict why reactivation occurs and why it happens differently with different drugs.

Their results suggest that anti-TNF therapy is highly likely to lead to many incidents of TB if used in areas where exposure to the TB pathogen is probable. However, they also propose that a TNF-modulating agent could be developed that could balance the requirement for reduction of inflammation with the necessity to maintain resistance to infection and microbial disease. In the mean time, modifying the dosage and timing of anti-TNF treatment could prevent reactivation, as could a complete regimen of antibiotic treatment for TB prior to anti-TNF treatment.


'/>"/>

Contact: Johanna Dehlinger
press@plos.org
415-624-1202
Public Library of Science
Source:Eurekalert

Page: 1

Related biology news :

1. Undesirable expatriates: Preventing the spread of invasive animals
2. Size matters: Preventing large mammal extinction
3. Controlling wildlife trade key to preventing health crises, study says
4. Preventing a pandemic: Study suggests strategies for containing a flu outbreak
5. Free HIV tests cheaper than charging when goal is preventing AIDS
6. UC Davis study finds HIV hiding from drugs in gut, preventing immune recovery
7. Pollution threatens coral health by preventing lesions from healing, UCF study shows
8. Opening windows may be the best way of preventing transmission of airborne infection
9. Scientists find missing enzyme for tuberculosis iron scavenging pathway
10. New vaccine protects more effectively against tuberculosis
11. Boosting The BCG Vaccine To Beat Tuberculosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
(Date:6/22/2016)... June 22, 2016 Research and Markets has ... report to their offering. ... 2014 from $29.3 billion in 2013. The market is expected to ... from 2015 to 2020, increasing from $50.6 billion in 2015 to ... forecasts during the forecast period (2015 to 2020) are discussed. As ...
(Date:6/22/2016)... 2016   ViaCyte, Inc. , a privately-held regenerative ... replacement therapy for the treatment of diabetes in clinical-stage ... Meeting.  ISSCR 2016, the Global Stem Cell Event, is ... in San Francisco.    ... follows:Event: , Focus Session: Tools for Basic and Applied ...
Breaking Biology Technology: